The clinical course of Patients Retreated with Teprotumumab for Thyroid Eye Disease
Author: Raymond Douglas
Base Hospital / Institution: Thrive Health
Rapid fire oral presentation
Abstract ID: 24-334
Purpose
Teprotumumab was recently approved for the treatment of thyroid eye disease (TED) in the US. Recent work suggests that a proportion of patients require further treatment with teprotumumab having completed one course. We review the clinical course of patients who have received a second course of treatment.
Methods
In this retrospective consecutive case series, the charts of all patients treated with teprotumumab were reviewed. All patients who had received more than one full course of therapy and had available data at the conclusion of treatment were included. The clinical activity score (CAS), proptosis (measured by Hertel exophthalmometry in mms), and the Gorman diplopia score were reviewed at baseline, at the end of the first course, at baseline for the second course, at the end of the second course. Finally, adverse events throughout both courses of treatment were reviewed.
Results
17 patients were included in the study. The reduction in the CAS did not differ between the first and second course of treatment (p = 0.15 study eye and p = 0.08 for the fellow eye). There was a greater reduction in proptosis in the study eye (p < 0.5) but not the fellow eye (p = 0.09). The reduction in diplopia was not different between the first and second course (p = 0.051). There were no significant differences in the incidence of muscle cramps, nausea, fatigue, diarrhea, plugged ears, tinnitus or menstrual irregularities between the first and second round of treatment
Conclusion
A second course of teprotumumab produces similar reductions in inflammation, proptosis and diplopia without a change in the adverse event profile.
Additional Authors
| First name | Last name | Base Hospital / Institution |
|---|---|---|
| Shoaib | Ugradar | Thrive Health |
